Pancreatic Cancer Research

ResearcherCatharina ZiekenhuisActive in the last 2 years

Hanneke W.M. van Laarhoven

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1274-5643; OpenAlex author ID A5031748554. Sources: OpenAlex.

Their work

Papers
110 (first author 2, last author 19)
Trials
0
Grants
0
Labs led
2
Collaborators
271
Papers, trials and grants by year

2015: 4 papers · 2016: 4 papers · 2017: 4 papers · 2018: 10 papers · 2019: 9 papers · 2020: 14 papers · 2021: 10 papers · 2022: 13 papers · 2023: 11 papers · 2024: 7 papers · 2025: 14 papers · 2026: 10 papers

Papers 50 of 110

  1. Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. Co-author DOI 10.1002/cam4.72306↗
  2. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Last author DOI 10.1002/ijc.70519↗
  3. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  4. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  5. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  6. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  7. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  8. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  9. Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. Co-author DOI 10.1097/j.pain.0000000000004059↗
  10. Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. Co-author DOI 10.1158/0008-5472.can-24-4707↗
  11. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  12. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  13. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Last author DOI 10.1002/ijc.35267↗
  14. Association of epigenetic landscapes with heterogeneity and plasticity in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2024.104573↗
  15. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Last author DOI 10.1016/j.eclinm.2024.103068↗
  16. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  17. KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer. Co-author DOI 10.1016/j.medj.2025.100601↗
  18. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Co-author DOI 10.1016/j.pan.2025.03.011↗
  19. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  20. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  21. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  22. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Last author DOI 10.1186/s12955-025-02440-5↗
  23. Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer. Co-author DOI 10.3390/ijms26115200↗
  24. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  25. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  26. MR Elastography of the Pancreas: Bowel Preparation and Repeatability Assessment in Pancreatic Cancer Patients and Healthy Controls. Co-author DOI 10.1002/jmri.28918↗
  27. Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study. Co-author DOI 10.1016/j.ejca.2024.114117↗
  28. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  29. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Co-author DOI 10.1016/j.trsl.2024.08.002↗
  30. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  31. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  32. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  33. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer. Co-author DOI 10.1002/ijc.34276↗
  34. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  35. Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data. Co-author DOI 10.1016/j.eclinm.2022.101747↗
  36. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient p… Co-author DOI 10.1080/0284186x.2023.2273898↗
  37. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  38. hENT1 as a Predictive Biomarker in PDAC-Letter. Co-author DOI 10.1158/1078-0432.ccr-22-3827↗
  39. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PAN… Co-author DOI 10.1186/s12885-023-10521-1↗
  40. Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation … Co-author DOI 10.1186/s13063-022-07036-8↗
  41. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  42. Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette St… First author DOI 10.3390/cancers15235603↗
  43. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Last author DOI 10.1001/jamaoncol.2022.0168↗
  44. Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?-Reply. Last author DOI 10.1001/jamaoncol.2022.4676↗
  45. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33916↗
  46. Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): pros… Co-author DOI 10.1007/s00423-022-02653-y↗
  47. Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. Co-author DOI 10.1007/s00520-021-06648-1↗
  48. The fear of cancer recurrence and progression in patients with pancreatic cancer. Last author DOI 10.1007/s00520-022-06887-w↗
  49. Deep learning DCE-MRI parameter estimation: Application in pancreatic cancer. Co-author DOI 10.1016/j.media.2022.102512↗
  50. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗

Closest collaborators

The 25 strongest of 271 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 69 shared papers, 2015–2026 · strength 8.80
  2. Johanna W. Wilmink · 63 shared papers, 2015–2026 · strength 8.38
  3. Judith de Vos‐Geelen · 26 shared papers, 2018–2026 · strength 4.31
  4. Maarten F. Bijlsma · 31 shared papers, 2015–2026 · strength 4.24
  5. Izaak Quintus Molenaar · 27 shared papers, 2016–2026 · strength 3.59
  6. Ignace H. J. T. de Hingh · 25 shared papers, 2015–2026 · strength 3.36
  7. Lydia G. van der Geest · 23 shared papers, 2016–2026 · strength 3.26
  8. Marjolein Y.V. Homs · 19 shared papers, 2020–2026 · strength 3.09
  9. Casper H.J. van Eijck · 23 shared papers, 2018–2026 · strength 3.09
  10. Hjalmar C. van Santvoort · 22 shared papers, 2018–2026 · strength 3.06
  11. Martijn W.J. Stommel · 17 shared papers, 2019–2026 · strength 2.92
  12. Bas Groot Koerkamp · 23 shared papers, 2018–2026 · strength 2.92
  13. Geert Kazemier M · 17 shared papers, 2017–2026 · strength 2.47
  14. Vincent Erwin de Meijer · 14 shared papers, 2020–2026 · strength 2.43
  15. Lois A. Daamen · 13 shared papers, 2019–2026 · strength 2.16
  16. Bert A. Bonsing · 14 shared papers, 2018–2026 · strength 1.89
  17. Nadia Haj Mohammad · 17 shared papers, 2015–2025 · strength 1.83
  18. Geertjan van Tienhoven · 15 shared papers, 2015–2026 · strength 1.72
  19. Paul Manoukian · 7 shared papers, 2021–2026 · strength 1.70
  20. Jeanin Elise van Hooft · 10 shared papers, 2017–2026 · strength 1.40
  21. Pauline A. J. Vissers · 7 shared papers, 2020–2026 · strength 1.38
  22. Simone Augustinus · 7 shared papers, 2022–2026 · strength 1.31
  23. Tessa Y. S. Le Large · 10 shared papers, 2017–2024 · strength 1.29
  24. Elisa Giovannetti · 10 shared papers, 2017–2024 · strength 1.29
  25. Esther N. Pijnappel · 7 shared papers, 2021–2025 · strength 1.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.